- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04571645
Dociparstat in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid Leukemia (AML)
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dociparstat Sodium in Combination With Standard Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
California
-
Orange, California, United States, 92868
- UC Irvine Medical Center
-
-
Kansas
-
Westwood, Kansas, United States, 66205
- University of Kansas Cancer Center
-
-
Kentucky
-
Louisville, Kentucky, United States, 40207
- Norton Cancer Institute, St. Matthews Campus
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70112
- Tulane University School of Medicine
-
-
Michigan
-
Detroit, Michigan, United States, 48202
- Henry Ford Health System
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55407
- Allina Health System / Virginia Piper Cancer Institute
-
-
New York
-
Hawthorne, New York, United States, 10595
- New York Medical College
-
New York, New York, United States, 10029
- Mount Sanai School of Medicine
-
-
North Carolina
-
Greenville, North Carolina, United States, 27834
- East Carolina University Vidant Medical Center
-
-
Ohio
-
Canton, Ohio, United States, 44718
- Gabrail Cancer Center
-
-
South Carolina
-
Spartanburg, South Carolina, United States, 29303
- Spartanburg Medical Gibbs Cancer Center
-
-
Texas
-
Dallas, Texas, United States, 75246
- Baylor
-
-
Utah
-
Salt Lake City, Utah, United States, 84112
- University of Utah / Huntsman Cancer Institute
-
-
Virginia
-
Charlottesville, Virginia, United States, 22903
- University of Virginia Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
A potential participant must have met all the following criteria to be eligible to participate in the study:
- Had newly-diagnosed, previously untreated acute myeloid leukemia (AML) (according to the World Health Organization criteria) with at least 20% blasts in the peripheral blood or bone marrow.
Was aged ≥18 years.
Adverse genetic risk (according to European LeukemiaNet [ELN] criteria), defined as nay of the following genetic abnormalities:
- t(6;9)(p23;q34.1); DEK-NUP214
- - t(v;11q23.3); KMT2A rearranged
- - t(9;22)(q34.1;q11.2); BCR-ABL1
- - inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM(EVI1)
- - -5 or del(5q); -7; -17/abn(17p)
- - Complex karyotype, monosomal karyotype
- - Wild-type NPM1 and FLT3-ITDhigh
- - Mutated RUNX1, mutated ASXL1, or mutated TP53 OR
Intermediate genetic risk (according to ELN criteria), defined as any of the following genetic abnormalities:
- Mutated NPM1 and FLT3-ITDhigh
- - Wild-type NPM1 without FLT3-ITD or with FLT3-ITDlow (without adverse-risk genetic lesions)
- - t(9;11)(p21.3;q23.3); MLLT3-KMT2A
- - Cytogenetic abnormalities not classified as favorable or adverse
- Had an Eastern Cooperative Oncology Group performance status of 0 to 2.
- Provided written informed consent to participate in the study.
Exclusion Criteria:
A potential participant who met any of the follow criteria was not eligible to participate in the study:
Leukemia exclusions:
- Had acute promyelocytic leukemia (t(15;17)), myeloid sarcoma without bone marrow involvement, or blast transformation of chronic myelogenous leukemia.
- Not applicable (criterion removed in Amendment 1 of the Clinical Study Protocol).
- Not applicable (criterion removed in Amendment 1 of the Clinical Study Protocol).
Had clinical evidence of central nervous system leukemia.
Prior/Concomitant Therapy:
Had previously received AML treatment, including Vyxeos (CPX-351, liposomal cytarabine and daunorubicin), gemtuzumab ozogamicin, or any other prohibited concomitant AML therapy previously received or anticipated to start during the study.
Note: Prior hydroxyurea and emergency leukapheresis to control white blood cell count were allowed. All-trans retinoic acid during workup and a single dose of intrathecal cytarabine and/or methotrexate was permitted for participants who were undergoing lumbar puncture to evaluate central nervous system involvement.
Were receiving any form of anticoagulant therapy (e.g., unfractionated heparin, low molecular weight heparin, coumadin, factor Xa inhibitors).
Note: Heparin flush of indwelling catheters was permitted.
- Received treatment with any other investigational agent within 28 days or 5 half-lives, whichever was longer, prior to baseline.
Underwent any major surgery or radiation therapy within 28 days prior to baseline.
Medical conditions:
- Had immediately life threatening, severe complications of leukemia such as pneumonia with hypoxia or shock, and/or disseminated intravascular coagulation.
- Had active or uncontrolled bleeding at the time of randomization; a bleeding disorder, either inherited or caused by disease; a history of known arterial-venous malformation, intracranial hemorrhage, or suspected or known cerebral aneurysm; or clinically significant (in the judgement of the Investigator) gastrointestinal bleeding within 3 weeks prior to randomization.
Had the presence of significant active or uncontrolled infection, including human immunodeficiency virus (HIV) or hepatitis B or C.
Note: Subjects with an infection who were receiving treatment (antibiotic, antifungal, or antiviral treatment) may have entered into the study but must have been afebrile and hemodynamically stable for ≥72 hours. Patients who had current evidence of invasive fungal infection (positive blood or tissue culture) must have had subsequent negative cultures to be eligible.
- Had active (uncontrolled, metastatic) second malignancy. Note: A second malignancy that was in remission was permitted if there was clinical evidence of disease stability for a period of greater than 6 months off cytotoxic chemotherapy that was documented by imaging, tumor marker studies, etc. Long-term nonchemotherapy treatment (e.g., hormonal therapy) was acceptable.
- Had psychiatric or neurological conditions that could have compromised participant safety or compliance.
Had a history of severe congestive heart failure or other cardiac disease that contraindicated the use of idarubicin or daunorubicin (e.g., cardiac ejection fraction <45%, as determined by echocardiography or multigated acquisition scan).
Diagnostic assessments:
- Had a corrected QT interval >480 msec.
- Had severe renal impairment, as determined by calculated creatinine clearance <30 mL/min or estimated glomerular filtration rate <30 mL/min/1.73 m2.
Had alanine aminotransferase or aspartate aminotransferase >3x the upper limit of normal (ULN) or total bilirubin >2x the ULN.
Other:
- Was a woman of childbearing potential who was pregnant, breastfeeding, and/or not using a highly effective method of contraception (consistent with local regulations regarding the methods of contraception for those participating in clinical studies).
- Had a history of allergy or hypersensitivity to heparin, pork, or any excipients in the dociparstat formulation.
- Had any other condition, including abnormal laboratory values that, in the judgement of the Investigator, could have put the participant at increased risk or interfered with the conduct or planned analyses of the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dociparstat
Treatment with standard intensive induction, reinduction, or consolidation chemotherapy and dociparstat 4 mg/kg intravenous (IV) bolus on Day 1, administered 30 minutes after completion of the first dose of idarubicin or daunorubicin, followed by dociparstat 0.25 mg/kg/hr via continuous IV infusion 24 hours daily for 5 or 7 days.
|
Dociparstat is a glycosaminoglycan derived from porcine heparin.
Other Names:
|
Placebo Comparator: Control
Treatment with standard intensive induction, reinduction, or consolidation chemotherapy and placebo intravenous (IV) bolus on Day 1, administered 30 minutes after completion of the first dose of idarubicin or daunorubicin, followed by placebo via continuous IV infusion 24 hours daily for 5 or 7 days.
|
0.9% Normal Saline
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Survival
Time Frame: Measured from randomization to date of death from any cause, up to 1 year.
|
Overall survival was defined for all study participants through 5 years after randomization. Overall survival was to be measured from the date of randomization to the date of death from any cause. Participants not known to have died at last follow-up contact were to be censored on the date they were last known to be alive. Due to early termination, subjects did not complete long term follow-up and efficacy (including overall survival outcome) was not analyzed. |
Measured from randomization to date of death from any cause, up to 1 year.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Event free survival
Time Frame: Measured from randomization up to 5 years
|
Event free survival (EFS) is defined as time to induction/reinduction treatment failure (within 42 days), relapse after complete remission (CR), or death from any cause.
|
Measured from randomization up to 5 years
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CMX-DS-003
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Myeloid Leukemia
-
University of PennsylvaniaActive, not recruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia, Refractory | Acute Myeloid Leukemia, PediatricUnited States
-
Terrence J Bradley, MDImago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New...RecruitingAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia, in RelapseUnited States
-
Bhavana BhatnagarCTI BioPharmaCompletedRecurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Therapy-Related Acute Myeloid LeukemiaUnited States
-
National Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
Washington University School of MedicineWithdrawnRefractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
C. Babis AndreadisGateway for Cancer Research; AVEO Pharmaceuticals, Inc.TerminatedAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingAcute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Therapy-Related Acute Myeloid LeukemiaUnited States
-
Jacqueline Garcia, MDEli Lilly and CompanyCompletedCombination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid LeukemiaRelapsed Adult Acute Myeloid Leukemia | Refractory Adult Acute Myeloid LeukemiaUnited States
-
University of NebraskaNational Cancer Institute (NCI)Active, not recruitingSecondary Acute Myeloid Leukemia | Therapy-Related Acute Myeloid Leukemia | Adult Acute Myeloid LeukemiaUnited States
Clinical Trials on Dociparstat
-
ChimerixTranslational Drug DevelopmentCompletedAcute Myeloid LeukemiaUnited States
-
ChimerixCompletedAcute Myeloid LeukemiaUnited States
-
ChimerixTranslational Drug DevelopmentTerminatedMetastatic Pancreatic CancerUnited States
-
ChimerixTerminatedSevere Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) | Acute Lung Injury | Coronavirus Disease 2019 (COVID-19)United States